Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/23500| Title: | Beyond HER2 and trastuzumab: heterogeneity, systems biology, and cancer origin research may guide the future for personalized treatment of very early but aggressive breast cancer |
| Institution and School/Department of submitter: | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής |
| Keywords: | Antibodies, Monoclonal/*therapeutic use,Antibodies, Monoclonal, Humanized,Antineoplastic Agents/therapeutic use,Breast Neoplasms/*drug therapy/enzymology/metabolism/*pathology,Disease-Free Survival,Female,Humans,Neoplasm Staging,Receptor, erbB-2/*antagonists & inhibitors/immunology,Receptors, Estrogen/metabolism,Receptors, Progesterone/metabolism |
| URI: | https://olympias.lib.uoi.gr/jspui/handle/123456789/23500 |
| ISSN: | 1527-7755 |
| Link: | http://www.ncbi.nlm.nih.gov/pubmed/20406920 http://jco.ascopubs.org/content/28/17/e279.full.pdf |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Roukos-2010-Beyond HER2 and tras.pdf | 52 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License
